Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Quetzal Therapeutics LLC has 2 pending office actions in Biotechnology & Pharmaceuticals. Both actions are assigned to 1 examiner, PALENIK, JEFFREY T, in 1 distinct art unit. PALENIK, JEFFREY T is the busiest examiner with 2 pending office actions. This concentration allows for a consistent prosecution strategy across both pending matters, as the same examiner is reviewing all pending work in the same art unit. This is the most concentrated possible structure for a portfolio with multiple pending actions.
The 1 distinct art unit indicates a very specific technical focus for the company's biotechnology innovations. Because both 2 pending office actions are under the same examiner, the company can leverage insights from one case to inform the strategy for the other. Practitioners should focus their efforts on understanding the specific preferences and past decisions of PALENIK, JEFFREY T. This concentrated profile simplifies the management of the portfolio, as there is only one examiner relationship and one set of art unit standards to navigate. The outcome of both pending matters will likely be influenced by the same examiner's perspective within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PALENIK, JEFFREY T | 2 | 53.6% | +27.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19349368 | HIGH SURFACE-AREA LYOPHILIZED COMPOSITIONS COMPRISING ARSENIC FOR ORAL ADMINISTRATION IN PATIENTS | PALENIK, JEFFREY T | 5d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19349368 | HIGH SURFACE-AREA LYOPHILIZED COMPOSITIONS COMPRISING ARSENIC FOR ORAL ADMINISTRATION IN PATIENTS | PALENIK, JEFFREY T | 5d |
| 18408664 | High Surface-Area Lyophilized Compositions Comprising Arsenic For Oral Administration In Patients | PALENIK, JEFFREY T | 48d |
| Art Unit | Apps |
|---|---|
| 1615 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19349368 | HIGH SURFACE-AREA LYOPHILIZED COMPOSITIONS COMPRISING ARSENIC FOR ORAL ADMINISTRATION IN PATIENTS | PALENIK, JEFFREY T | 1615 | §102§103 | Final Rejection | 5d | Pending | Oct 03, 2025 |
| 18408664 | High Surface-Area Lyophilized Compositions Comprising Arsenic For Oral Administration In Patients | PALENIK, JEFFREY T | 1615 | §103Other | Non-Final OA | 48d | Pending | Jan 10, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial